Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines

Sanaria Inc. has developed methods to manufacture, purify and cryopreserve aseptic Plasmodium falciparum (Pf) sporozoites (SPZ), and is using this platform technology to develop an injectable PfSPZ-based vaccine that provides high-grade, durable protection against infection with Pf malaria. Several candidate vaccines are being developed and tested, including PfSPZ Vaccine, in which the PfSPZ are attenuated by irradiation, PfSPZ-CVac, in which fully infectious PfSPZ are attenuated in vivo by concomitant administration of an anti-malarial drug, and PfSPZ-GA1, in which the PfSPZ are attenuated by gene knockout. Forty-three research groups in 15 countries, organized as the International PfSPZ Consortium (I-PfSPZ-C), are collaborating to advance this program by providing intellectual, clinical, and financial support. Fourteen clinical trials of these products have been completed in the USA, Europe and Africa, two are underway and at least 12 more are planned for 2015–2016 in the US (four trials), Germany (2 trials), Tanzania, Kenya, Mali, Burkina Faso, Ghana and Equatorial Guinea. Sanaria anticipates application to license a first generation product as early as late 2017, initially to protect adults, and a year later to protect all persons >6 months of age for at least six months. Improved vaccine candidates will be advanced as needed until the following requirements have been met: long-term protection against natural transmission, excellent safety and tolerability, and operational feasibility for population-wide administration. Here we describe the three most developed whole PfSPZ vaccine candidates, associated clinical trials, initial plans for licensure and deployment, and long-term objectives for a final product suitable for mass administration to achieve regional malaria elimination and eventual global eradication.

[1]  W. Richards.  Active Immunization of Chicks against Plasmodium gallinaceum by Inactivated Homologous Sporozoites and Erythrocytic Parasites , 1966, Nature.

[2]  S. Hoffman,et al.  Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites , 2014, The American journal of tropical medicine and hygiene.

[3]  D. Herrington,et al.  Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. , 1990, Bulletin of the World Health Organization.

[4]  P. F. Russell,et al.  THE IMMUNIZATION OF FOWLS AGAINST MOSQUITO-BORNE PLASMODIUM GALLINACEUM BY INJECTIONS OF SERUM AND OF INACTIVATED HOMOLOGOUS SPOROZOITES , 1942, The Journal of experimental medicine.

[5]  Myron M. Levine,et al.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites , 1987, Nature.

[6]  D. Bj,et al.  Tropical malaria contracted the natural way in the Netherlands , 1979 .

[7]  J. Meuwissen,et al.  Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in vitro culture. , 1981, Tropical and geographical medicine.

[8]  G Losonsky,et al.  Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. , 1993, The Journal of infectious diseases.

[9]  D. Carucci,et al.  DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.

[10]  S. Hoffman,et al.  Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers under Chloroquine Prophylaxis: A Randomized Controlled Trial , 2016, The American journal of tropical medicine and hygiene.

[11]  S. Hoffman,et al.  Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites , 2013, The American journal of tropical medicine and hygiene.

[12]  S. Hoffman,et al.  Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection , 2014, Front. Microbiol..

[13]  S. Hoffman,et al.  Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection , 2015, The American journal of tropical medicine and hygiene.

[14]  Andrew Pollard,et al.  DEATHS DURING MOUNTAINEERING AT EXTREME ALTITUDE , 1988, The Lancet.

[15]  D. Clyde,et al.  Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. , 1975, The American journal of tropical medicine and hygiene.

[16]  A. Folgori,et al.  Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation , 2013, Nature Communications.

[17]  Yuming Guo,et al.  The effect of air pollution on human physiological function in China: a longitudinal study , 2015, The Lancet.

[18]  S. Hoffman,et al.  SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE , 1987, The Lancet.

[19]  S. Hoffman,et al.  NF135.C10: A New Plasmodium falciparum Clone for Controlled Human Malaria Infections , 2012, The Journal of infectious diseases.

[20]  S. Hoffman,et al.  Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. , 1993, The American journal of tropical medicine and hygiene.

[21]  S. C. T. P. Rts.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial , 2015, The Lancet.

[22]  K. Sell,et al.  Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. , 1979, Bulletin of the World Health Organization.

[23]  Patricia De la Vega,et al.  Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. , 2002, The Journal of infectious diseases.

[24]  K. Rieckmann,et al.  Human immunization with attenuated sporozoites. , 1990, Bulletin of the World Health Organization.

[25]  S. Hoffman,et al.  Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya , 2015, Malaria Journal.

[26]  Adrian J F Luty,et al.  Protection against a malaria challenge by sporozoite inoculation. , 2009, The New England journal of medicine.

[27]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[28]  S. Hoffman,et al.  A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites , 2014, eLife.

[29]  Clyde Df.  Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. , 1990 .

[30]  K. Sell,et al.  Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. , 1974, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[31]  B. Delemarre,et al.  [Tropical malaria contracted the natural way in the Netherlands]. , 1979, Nederlands tijdschrift voor geneeskunde.

[32]  I. Kleinschmidt,et al.  Five years of malaria control in the continental region, Equatorial Guinea , 2013, Malaria Journal.

[33]  T. Burkot,et al.  Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[34]  S. Hoffman,et al.  Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates , 2015, Malaria Journal.

[35]  S. Hoffman,et al.  Two Plasmodium 6‐Cys family‐related proteins have distinct and critical roles in liver‐stage development , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  J. Weber,et al.  Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. , 1984, Science.

[37]  D. Clyde,et al.  Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. , 1977, Experimental parasitology.

[38]  J. Vanderberg,et al.  Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei , 1967, Nature.

[39]  V. Nussenzweig,et al.  Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. , 1979, Bulletin of the World Health Organization.

[40]  D. Clyde.  Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. , 1990, Bulletin of the World Health Organization.

[41]  Jonathan Crabtree,et al.  Comparative genomics of the neglected human malaria parasite Plasmodium vivax , 2008, Nature.

[42]  S. Hoffman,et al.  Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe , 2013, PloS one.

[43]  R. Sauerwein,et al.  Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study , 2011, The Lancet.

[44]  J. Vanderberg,et al.  Immunization of man against sporozite-induced falciparum malaria , 1973, The American journal of the medical sciences.

[45]  S. Hoffman,et al.  Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. , 2013, Vaccine.

[46]  S. Hoffman,et al.  Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres , 2015, Malaria Journal.

[47]  Peter G. Kremsner,et al.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. , 2015 .

[48]  Mario Roederer,et al.  Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine , 2013, Science.

[49]  R. Miller,et al.  Specificity of protection of man immunized against sporozoite‐induced falciparum malaria , 1973, The American journal of the medical sciences.

[50]  Sumana Chakravarty,et al.  Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria , 2010, Human vaccines.

[51]  S. Hoffman,et al.  The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. , 2009, The Journal of infectious diseases.

[52]  E. R. James,et al.  Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity , 2011, Science.

[53]  P. F. Russell,et al.  Active Immunization of Fowls against Sporozoites but not Trophozoltes of Plasmodium gallinaceum by Injections of Homologous Sporozoites. , 1942 .